Ispronicline

Ispronicline (TC-1734, AZD-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.^[1]

ATC code

• none

CAS Number

• 252870-53-4 ^Y

PubChem CID

• 9824145

ChemSpider

• 7999892 ^N

Quick facts Clinical data, ATC code ...

Ispronicline

Clinical data
ATC code	none
Identifiers
IUPAC name (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine
CAS Number	252870-53-4 Y
PubChem CID	9824145
ChemSpider	7999892 N
UNII	3E05NBH9V5
KEGG	D08935 Y
CompTox Dashboard (EPA)	DTXSID001027512
Chemical and physical data
Formula	C14H22N2O
Molar mass	234.343 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](C/C=C/C1=CC(=CN=C1)OC(C)C)NC
InChI InChI=1S/C14H22N2O/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15H,6H2,1-4H3/b7-5+/t12-/m0/s1 N Key:RPCVIAXDAUMJJP-PZBABLGHSA-N N
NY (what is this?)  (verify)

Close

It has also progressed to phase II as a potential treatment for ADHD. With dosages of 50 mg/day showing a significant improvement in ADHD symptoms^[2][3]

Ispronicline is subtype-selective, binding primarily to the α4β2 subtype. It has antidepressant, nootropic and neuroprotective effects.^{[medical citation needed]}

Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being dizziness and headache.^{[4][5][6][7][8]} However, mid-stage clinical trials failed to show sufficient efficacy to continue development as a pharmaceutical drug.^[1]